Angling Pfizer, AstraZeneca jumps into commercial PD-(L)1 fight in China
Is a Big Pharma commercial showdown brewing in China’s PD-(L)1 market?
Months after Pfizer outlined a sprawling $200 million pact with CStone partly to market its experimental PD-L1 in China, AstraZeneca is wading into the same waters by lassoing certain commercial rights to toripalimab from Junshi Biosciences.
Notably, both have their own checkpoint drugs. But unlike Pfizer’s Bavencio, AstraZeneca’s Imfinzi is actually approved in China for unresectable non-small cell lung cancer. And in toripalimab, the British drugmaker is scoring a more mature drug that earned China’s first-ever approval for a homegrown PD-1 back in 2018.